Auteur G. SUBRAMANIAM

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Common data elements for substance use disorders in electronic health records: the NIDA Clinical Trials Network experience [For debate]

U. E. GHITZA ; R. E. GORE-LANGTON ; R. LINDBLAD ; D. SHIDE ; G. SUBRAMANIAM ; B. TAI | 2013
Dans Addiction (Vol.108, n°1, January 2013) Article : Périodique

Aims: Electronic health records (EHRs) are essential in improving quality and enhancing efficiency of health-care delivery. By 2015, medical care receiving service reimbursement from US Centers for Medicare and Medicaid Services (CMS) must show [...]

Plus d'info

Ajouter à la sélection

Lien externe

Depressive symptoms in adolescents during residential treatment for substance use disorders

G. SUBRAMANIAM ; L. L. LEWIS ; M. L. STITZER ; M. J. FISHMAN | 2004
Périodique

ENGLISH : This study examines the demographic and clinical correlates and time course of depressive symptoms among abstinent adolescents with substance use disorders (SUD) during residential treatment. Fifty-six adolescents were administered t[...]

Plus d'info

Ajouter à la sélection

Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial

G. E. WOODY ; S. A. POOLE ; G. SUBRAMANIAM ; DUGOSH K. ; M. BOGENSCHUTZ ; P. ABBOTT ; A. A. PATKAR ; PUBLICKER M. ; MCCAIN K. ; J. SHARPE POTTER ; R. FORMAN ; VETTER V. ; L. McNICHOLAS ; J. BLAINE ; K. G. LYNCH ; P. J. FUDALA | 2008
Dans Journal of the American Medical Association (Vol.300, n°17, November 5, 2008) Article : Périodique

Context: The usual treatment for opioid-addicted youth is detoxification and counseling. Extended medication-assisted therapy may be more helpful. Objective: To evaluate the efficacy of continuing buprenorphine-naloxone for 12 weeks vs detoxif[...]

Plus d'info

Ajouter à la sélection

Lien externe